If stopping means regaining most of the weight, then stopping is not really an option. These become maintenance drugs, taken indefinitely. That reality makes dosing efficiency a crucial question.

Early research on every-other-week dosing is giving us a possible answer. The data is still thin. The sample sizes are small. But the early signals suggest that maintaining weight loss might not require full weekly doses.

In a 2026 Scripps Clinic case series of 30 patients (Wong et al., Obesity), every-other-week dosing held weight loss for an average of 36 weeks after patients had reached their target on weekly doses, weight stayed essentially flat (87.9 → 74.1 → 72.4 kg). The numbers are small. The study is retrospective, not an RCT. But it suggests the body might be able to hold onto weight loss with less frequent signaling.

This matters for two reasons. First, less frequent dosing might mean lower cumulative exposure to these compounds over years and decades. Second, it might be more convenient. Weekly dosing is manageable, but every-other-week dosing is better.

But the evidence is preliminary. We need larger, longer studies to know if every-other-week dosing actually works for real-world maintenance. We need to know how long it holds. We need to understand whether the answer is the same for everyone or whether it varies based on individual factors like the ones that make initial response so different.

The question is shifting from whether people can maintain weight loss to how efficiently the body can maintain it.